Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in nonalcoholic steatohepatitis in rats
| Project/Area Number |
21790687
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Aichi Medical University |
|---|
Principal Investigator |
NAKADE Yukiomi Aichi Medical University, 医学部, 講師 (70431400)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | アンギオテンシン受容体拮抗剤 / NASH / 肝発癌予防 / コリン欠乏食 / 肝脂肪化 / 肝線維化 |
|---|
| Research Abstract |
To investigate whether angiotensin II receptor blocker could prevent the development of NASH related hepatocellular carcinoma (HCC), we examined the effect of ARB on choline-deficientL-aminoacid-defined (CDAA) diet NASH model. Twenty-four week-CDAA diet produced liver cirrhosis, and then CDAA diet for another 24 week aggravated liver cirrhosis, and produced HCC. On the other hand, telmisartan, a novel ARB, improved hepatic fibrosis and protected hepatic carcinogenesis even after 24-week CDAA diet feeding. These finding indicate that telmisartan has a therapeutic potential for NASH induced production of HCC even after hepatic fibrosis had been developed.
|
Report
(3 results)
Research Products
(24 results)
